Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) is a clinical-stage biotech company focused on psychedelic-inspired medicines and digital therapeutics for neuropsychiatric disorders. Its lead candidate, MM-120 (LSD derivative), targets generalized anxiety disorder and ADHD, with additional programs in 5-HT2A modulation. MindMed integrates pharmacology with digital biomarkers to personalize treatment outcomes. It provides investors with speculative exposure to the evolving landscape of mental health therapeutics and psychedelic drug development.